Form 4: Oramed Pharmaceuticals CFO Avraham Gabay Receives Stock Grant

Avraham Gabay, CFO of Oramed Pharmaceuticals, was granted 140,040 Restricted Stock Units (RSUs) on June 21, 2024.

Summary

• On June 21, 2024, Avraham Gabay, the Chief Financial Officer of Oramed Pharmaceuticals Inc., received a grant of 140,040 Restricted Stock Units (RSUs).
• 93,360 of these RSUs will vest on June 18, 2026.
• The remaining 46,680 RSUs will vest in four equal quarterly installments of 11,670 starting September 18, 2026.
• Each RSU converts into one share of Oramed Pharmaceuticals' common stock.

Sentiment

Score: 7

Explanation: The announcement is neutral to positive, reflecting standard executive compensation practices. The vesting schedule suggests a long-term commitment from the CFO.

Positives

• The grant of RSUs to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Future Outlook

The vesting schedule of the RSUs suggests a long-term commitment from the CFO to the company's success.

Industry Context

Stock grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the pharmaceutical industry.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) also utilize stock-based compensation to incentivize their executives.
• The vesting schedule is fairly standard, with multi-year vesting periods being common to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the CFO's interests with the company's long-term performance.

Key Dates